What question did this study set out to answer?

To assess the effects of irbesartan, alone or in combination with hydrochlorothiazide, on blood pressure, metabolic parameters, microalbuminuria, and cardiovascular risk in patients with hypertension and type 2 diabetes.

September 2, 2004Current Medical Research and Opinion

The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic patients: an observational study in 16 600 patients in primary care

View Full Paper

Ask AI

Bookmark

Why the study?

Does irbesartan improve blood pressure, microalbuminuria, and calculated cardiovascular risk in patients with hypertension and type 2 diabetes?

Population

16,600 patients with clinical diagnoses of hypertension and type 2 diabetes, mean age 62.2 years, 51.3% men…

Design

Cohort, open

Follow-up

3 months

Authors

PBPeter BramlagePreventive Cardiology DPD PittrowTechnische Universität Dresden WKWilhelm KirchGeneral / Preventive / Lipids

Discussion

Member takes

Implication

Associated with BP, microalbuminuria, and SCORE reductions in hypertensive T2D; hypothesis-generating for outcomes pending randomized trials.

Key Points

To assess the effects of irbesartan, alone or in combination with hydrochlorothiazide, on blood pressure, metabolic parameters, microalbuminuria, and cardiovascular risk in patients with hypertension and type 2 diabetes.
Multicenter, prospective, open phase IV study with a 3-month follow-up involving 16,600 patients with clinically diagnosed hypertension and type 2 diabetes in primary care.
Assessed blood pressure sphygmometrically, microalbuminuria with semi-quantitative urine dipsticks, metabolic markers, and 10-year SCORE cardiovascular risk.
Mean systolic and diastolic blood pressure decreased by 22.3 mmHg and 11.2 mmHg, respectively, after 3 months across diverse subgroups.
Microalbuminuria rates declined from 45.6% to 30.6% (a 32.9% relative reduction), and 10-year SCORE cardiovascular risk decreased from 9.8% to 5.7% (a 58% relative reduction).
Adverse events occurred in only 0.3% of participants, while lipid profiles, blood glucose, HbA1c, and body weight showed significant improvements or favorable trends.

Structured PICO

Does irbesartan improve blood pressure, microalbuminuria, and calculated cardiovascular risk in patients with hypertension and type 2 diabetes?

Population

16,600 patients with clinical diagnoses of hypertension and type 2 diabetes, mean age 62.2 years, 51.3% men, 53.9% overweight, and 26.4% obese.

Intervention

Irbesartan as monotherapy, or in fixed combination with hydrochlorothiazide, for 3 months.

Outcome

Systolic (SBP) and diastolic (DBP) blood pressure reduction, proportion of patients with microalbuminuria, and cardiovascular risk calculated based on the SCORE score, each after a follow-up of 3 months compared to baseline.surrogate

In a large primary care cohort of patients with hypertension and type 2 diabetes, irbesartan treatment for 3 months significantly reduced blood pressure, microalbuminuria, and calculated 10-year cardiovascular risk.

Cite This Study

Bramlage et al. (2004) studied this question.

synapsesocial.com/papers/6a8cebdd2c3e0995d771b98e https://doi.org/10.1185/030079904x3861

Topics

Hypertension management Women and heart disease Cardiovascular prevention

View Full Paper

Ask AI

Bookmark

Implication

Associated with BP, microalbuminuria, and SCORE reductions in hypertensive T2D; hypothesis-generating for outcomes pending randomized trials.

The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic patients: an observational study in 16 600 patients in primary care

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic patients: an observational study in 16 600 patients in primary care

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider